Summer Intern Platform Biology

Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.

In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and "undruggable" targets, the company has three investigational clinical-stage programs currently enrolling: ARV-102 for the treatment of patients with neurodegenerative disorders,ARV-393 for the treatment of patients with relapsed/refractory non-Hodgkin Lymphoma and potentially other lymphomas, and ARV-806, a KRAS G12D PROTAC for the treatment patients with solid tumors with KRAS G12D mutations.

On August 8th 2025, the U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for vepdegestrant- an investigational, orally bioavailable PROTAC estrogen receptor degrader- for its use as a monotherapy in the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In September 2025, Arvinas and Pfizer announced their plan to jointly select a third party for the out-licensing and commercialization of vepdegestrant.

In April 2024, Arvinas entered into a transaction with Novartis, including a global license agreement for the development and commercialization of the clinical stage PROTAC androgen receptor protein degrader ARV-766 for the treatment of prostate cancer. The transaction closed in May 2024.

#Team Arvinas is made up of passionate and curious employees, whose diverse thoughts and perspectives are highly valued. Arvinas employees embrace the freedom to pursue innovation, think creatively, and give back. They are driven by the company's values and mission - to improve the lives of patients with serious diseases by pioneering therapies created with our revolutionary PROTAC protein degradation platform.

We're really excited about the work we're doing inside and outside of Arvinas, and think you will be, too. But don't just take our word for it - learn more about life at Arvinas and what employees have to say.

For more information, please visit

Position Summary

The Platform Biology summer internship position at Arvinas will focus on evaluating and developing 3D biology to include automation and high-content imaging to support Oncology and Neuroscience. This position will involve cell biology and biochemical techniques, use of automation equipment, and high-content imaging. The candidate will join a collaborative, multi-disciplinary team of biologists, biochemists, biophysicists, and chemists. This is a laboratory-based role that will work to automate the biology and staining of 3D spheroids (and possibly organoids) for deeper understanding of and screening for novel PROTACs.

We are looking for a passionate and highly motivated individual who is enthusiastic about novel therapeutic applications, such as degraders, and wants to contribute to exploring new modalities of targeting proteins for degradation across neuroscience, oncology and immune-oncology space.

This training opportunity allows the individual to learn the process of early drug discovery in a collaborative environment.

This position reports to a Senior Research Scientist, Platform Biology and will be located at our headquarters in New Haven, CT.

Principal Responsibilities

Key responsibilities of this role include, but are not limited to:

* Cell culture including sterile technique for mammalian cell lines

* Live-cell assays to monitor, image and analyze 3D spheroids

* Cellular assays working to fix, permeabilize, and use immunofluorescence staining to research methods for 3D spheroid marker infiltration including tissue…